Polaris Partners

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Livara Health specializes in non-invasive, personalized treatment for musculoskeletal conditions. Its platform offers a data-driven six-week program for back pain relief, customized based on patient assessment, along with coaching support.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

August Bioservices, LLC is a contract development and manufacturing organization (CDMO) based in Nashville, Tennessee, with an additional office in Celina, Tennessee. Established in 2017, the company specializes in offering a wide range of services for drug discovery, pharmaceutical development, and clinical manufacturing. Its research services encompass target validation, functional characterization, assay development, drug discovery, protein engineering, and both in vitro and in vivo testing. In the pharmaceutical development arena, August Bioservices provides formulation, process design, optimization, scale-up, and analytical method development. The company's clinical manufacturing capabilities include clinical trial supply, cGMP non-sterile and bulk manufacturing, aseptic fill and finish, and quality control. Additionally, it offers various testing services, such as pregnancy testing and viral disease testing, to clients in the pharmaceutical and biotechnology sectors. August Bioservices was previously known as PMI BioPharma Solutions until its name change in July 2020.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Folx Health is a Boston-based telehealth platform founded in 2020, specializing in digital healthcare services tailored for the LGBTQIA+ community. It offers access to queer and trans clinicians, focusing on gender-affirming hormone therapy, sexual health, and family creation services.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Sonrai Security provides a comprehensive enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. Its flagship product, Dig, uses advanced graph technology to identify and monitor relationships between identities and data within public clouds. The platform automates workflows, remediation, and prevention capabilities across cloud and security teams, ensuring end-to-end security.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Hummingbird Bioscience employs systems biology to uncover disease mechanisms and uses computational platforms for discovering and engineering innovative biotherapeutics. Its pipeline includes HMBD-001 (anti-HER3 antibody) and HMBD-002 (anti-VISTA antibody), both in cancer treatment. The company collaborates strategically with Cancer Research UK and Amgen.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Armorblox, Inc. is a cybersecurity company founded in 2017 and based in Cupertino, California. It specializes in developing data security solutions that focus on protecting the human layer within organizations. Utilizing advanced machine learning and artificial intelligence techniques, Armorblox addresses identity-based attacks and data loss, providing comprehensive security for its clients. The company's innovative approach aims to enhance overall data protection and safeguard sensitive information in an increasingly complex digital landscape.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Sonrai Security provides a comprehensive enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. Its flagship product, Dig, uses advanced graph technology to identify and monitor relationships between identities and data within public clouds. The platform automates workflows, remediation, and prevention capabilities across cloud and security teams, ensuring end-to-end security.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Thirty Madison is a digital health company specializing in personalized treatments for chronic conditions. It operates platforms like Keeps (hair loss), Cove (migraines), Picnic (allergies), Facet (skin conditions), and Nurx (sexual health). Founded in 2016, it aims to empower individuals with accessible, effective care tailored to their specific needs.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Proof operates as a technology company specializing in secure digital transactions. It provides an identity-assured transaction management platform that verifies the identities of individuals engaging in online business dealings. By confirming identities and securing transactions, Proof helps protect both businesses and their customers from fraudulent activities, fostering trust in digital environments.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

FloQast is a software company specializing in financial close management. It offers tools to streamline the month-end close process, improve collaboration among accounting teams, and enhance accuracy in financial reporting. FloQast's platform provides features such as task management, documentation, reconciliation, and reporting, integrating with various accounting systems like QuickBooks, NetSuite, and SAP.

OM1 is a digital health company that provides an outcome management platform for healthcare organizations to measure, forecast, and compare patient outcomes. Its platform aggregates and analyzes clinical and patient-reported data to meet outcomes requirements in value-based care programs, CMS bundles, and private arrangements. The solution uses predictive and prescriptive analytics to identify risks, cost drivers, and opportunities to improve clinical and financial performance across the care continuum. By delivering AI-driven insights, OM1 helps hospitals and health systems demonstrate outcomes to stakeholders, support benchmarking and decision-making, and drive more precise care management. The company also maintains specialized registries for collaborations, including systemic lupus erythematosus, to support research and performance improvement. Through gathering and enriching diverse clinical data, OM1 aims to establish a higher standard for health outcomes information and enable more informed, value-based care.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Recurly, Inc. is a provider of enterprise-class subscription management and billing solutions aimed at optimizing revenue growth for businesses across various industries, including digital media, streaming, publishing, SaaS, consumer goods, and professional services. Founded in 2009 and headquartered in San Francisco, California, with additional offices in Boulder, Colorado, and New Orleans, Louisiana, Recurly simplifies the complexities of subscription billing and revenue optimization. Its platform facilitates recurring billing automation, offering features such as customizable hosted billing pages, account management services, and actionable insights to enhance decision-making. By reducing subscriber churn and improving operational efficiency, Recurly enables businesses to quickly integrate payment solutions and focus on growth. The company is also a Level 1 PCI compliant service provider, which minimizes costs associated with PCI compliance for its clients.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Proof operates as a technology company specializing in secure digital transactions. It provides an identity-assured transaction management platform that verifies the identities of individuals engaging in online business dealings. By confirming identities and securing transactions, Proof helps protect both businesses and their customers from fraudulent activities, fostering trust in digital environments.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Founded in Vermont in 2012, Caledonia Spirits is a craft distillery dedicated to supporting local agriculture. It produces gin and vodka using locally sourced ingredients like grains and honey, aiming to add value to the work of Vermont farmers while honoring traditional spirits-making techniques.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

KenSci Inc. is a healthcare technology company that specializes in developing a machine learning platform aimed at improving risk prediction for healthcare providers and payers. Founded in 2015 and headquartered in Seattle, Washington, with additional offices in Hyderabad and Singapore, KenSci's platform integrates and analyzes data from various sources, including clinical records, claims, and patient-generated information. This enables healthcare organizations to identify clinical, financial, and operational risks, allowing for earlier interventions that can save costs and improve patient outcomes. The platform offers a library of pre-built models and modular solutions, facilitating seamless integration into existing workflows to enhance hospital operations and care coordination. By leveraging Explainable AI, KenSci ensures that its risk-based predictions are both efficient and accountable, ultimately supporting the delivery of better healthcare.

Drizly is an online alcohol marketplace and liquor retail platform that enables on-demand delivery and shipping of beer, wine and spirits. It partners with retailers to bring their inventory online across 235 markets, offering a broad selection to consumers of legal drinking age and a transparent, personalized shopping experience. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly helps retailers reach new customers and gain market and customer insights, supporting growth in sales. The platform also supports ordering of beverages along with mixers and garnishes, enabling customers to order without visiting a store.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions to enhance patient outcomes in surgical and obstetric settings. Founded in 2011 and headquartered in Los Altos, California, Gauss Surgical develops the Triton system, which includes various models suited for different medical needs. Triton assists healthcare professionals in monitoring and estimating blood loss during procedures, allowing for timely intervention in cases of hemorrhage. The system offers objective metrics for blood loss, thereby facilitating better clinical decision-making regarding transfusions. Serving the healthcare sector primarily in the United States, Gauss Surgical's products are designed to integrate seamlessly into existing medical practices, using sophisticated algorithms and HIPAA-compliant technology to deliver accurate monitoring in real time.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies to treat serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer.

Twistlock Inc. is a provider of comprehensive security solutions for cloud-native applications, focusing on Docker container security for DevOps environments. Founded in 2015, the company offers a suite of products designed to protect applications throughout their development lifecycle and into production. Its flagship product, Twistlock, enables developers and security teams to safeguard container-based applications with features such as vulnerability management, compliance, access control, and runtime defense. Twistlock's Trust component scans images and registries to identify vulnerabilities and configuration errors, while Twistlock Runtime delivers real-time threat protection and policy enforcement. The company is trusted by a significant portion of the Fortune 100 and is headquartered in Portland, Oregon, with additional offices in New York City, Baton Rouge, London, and Herzliya, Israel. As of July 2019, Twistlock operates as a subsidiary of Palo Alto Networks, Inc.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Pointy is a company founded in 2014 that assists retail stores in establishing an online presence for their products. It develops a product tracking device that integrates with point-of-sale systems to automatically generate online product listings. When items are scanned through this system, they are instantly displayed on a product page, allowing local stores to showcase their inventory to potential customers searching online. This service enhances visibility for retailers and facilitates easier access for consumers seeking local products.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

Ajax Health is a venture capital firm dedicated to the healthcare sector. It invests across stages in medical devices, medtech, healthcare services, digital health, biotechnology and healthcare information technology, aiming to advance innovative solutions that address major healthcare challenges. Founded in 2017, the firm is headquartered in Menlo Park, California, with an additional office in New York City. Ajax Health seeks to accelerate medical innovation through capital and capabilities to support portfolio companies.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

OM1 is a digital health company that provides an outcome management platform for healthcare organizations to measure, forecast, and compare patient outcomes. Its platform aggregates and analyzes clinical and patient-reported data to meet outcomes requirements in value-based care programs, CMS bundles, and private arrangements. The solution uses predictive and prescriptive analytics to identify risks, cost drivers, and opportunities to improve clinical and financial performance across the care continuum. By delivering AI-driven insights, OM1 helps hospitals and health systems demonstrate outcomes to stakeholders, support benchmarking and decision-making, and drive more precise care management. The company also maintains specialized registries for collaborations, including systemic lupus erythematosus, to support research and performance improvement. Through gathering and enriching diverse clinical data, OM1 aims to establish a higher standard for health outcomes information and enable more informed, value-based care.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

FloQast is a software company specializing in financial close management. It offers tools to streamline the month-end close process, improve collaboration among accounting teams, and enhance accuracy in financial reporting. FloQast's platform provides features such as task management, documentation, reconciliation, and reporting, integrating with various accounting systems like QuickBooks, NetSuite, and SAP.

Lob designs and develops APIs for businesses to automate direct mail services. It offers postcards, letters, checks, address verification, and campaign tracking. With over 7,000 customers ranging from Fortune 500 companies to individual developers, Lob improves data quality and reduces mail processing time.

Twistlock Inc. is a provider of comprehensive security solutions for cloud-native applications, focusing on Docker container security for DevOps environments. Founded in 2015, the company offers a suite of products designed to protect applications throughout their development lifecycle and into production. Its flagship product, Twistlock, enables developers and security teams to safeguard container-based applications with features such as vulnerability management, compliance, access control, and runtime defense. Twistlock's Trust component scans images and registries to identify vulnerabilities and configuration errors, while Twistlock Runtime delivers real-time threat protection and policy enforcement. The company is trusted by a significant portion of the Fortune 100 and is headquartered in Portland, Oregon, with additional offices in New York City, Baton Rouge, London, and Herzliya, Israel. As of July 2019, Twistlock operates as a subsidiary of Palo Alto Networks, Inc.

Drizly is an online alcohol marketplace and liquor retail platform that enables on-demand delivery and shipping of beer, wine and spirits. It partners with retailers to bring their inventory online across 235 markets, offering a broad selection to consumers of legal drinking age and a transparent, personalized shopping experience. Founded in 2012 and headquartered in Boston, Massachusetts, Drizly helps retailers reach new customers and gain market and customer insights, supporting growth in sales. The platform also supports ordering of beverages along with mixers and garnishes, enabling customers to order without visiting a store.

Qstream, Inc. is a software company that specializes in developing a mobile sales acceleration platform designed to enhance job proficiency and influence behavior within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves clients across various sectors, including technology, financial services, and life sciences. The company operates engineering facilities in Dublin, Ireland, and Hood River, Oregon, while maintaining sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco. Qstream's micro-learning platform enables organizations to manage and measure the human aspects of sales performance, providing analytics-driven insights that facilitate team excellence.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, the company can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide range of clinical challenges. SQZ Biotech aims to create well-tolerated and effective cell therapies that enhance patient experiences compared to traditional approaches. With its commitment to internal research and strategic partnerships, SQZ is working to advance a new generation of cell therapies through both immune activation and immune suppression methods, showcasing its potential to transform treatment options for patients.

US HealthVest is a behavioral healthcare firm that focuses on transforming the psychiatric hospital sector. The company's business model centers on developing new facilities as well as acquiring existing ones that have untapped potential. Each facility is designed to provide a range of services tailored to meet the diverse needs of various patient populations. The leadership team at US HealthVest has a proven track record in the psychiatric hospital industry, having previously established and sold successful businesses, including Ascend Health, which operated nine freestanding facilities and nearly 900 beds before its acquisition by Universal Health Services in 2012. The firm's predecessor, Heartland Health Developments, also specialized in psychiatric care and was sold to Psychiatric Solutions in 2004.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Boxever Ltd. is a Dublin-based company that specializes in customer intelligence as a service for the travel industry. Founded in 2010, Boxever provides a digital optimization platform that leverages data and artificial intelligence to enhance customer interactions and experiences. Its main offerings include BOXEVER TX, which visualizes the customer journey, and TX-CORE, a traveler experience management solution that helps clients anticipate customer needs. Additionally, the platform features TX-NOW, an offer management tool, and serves as a comprehensive customer data platform (CDP) that integrates information from various online and offline sources. Boxever collaborates with prominent brands such as Emirates and Ryanair, aiming to transform customer engagement through personalized experiences and data-driven decision-making.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.